Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms
Ghaith Abu-Zeinah, Gabriela Hobbs, Brandi N Reeves, Abdulraheem Yacoub, Joseph M Scandura · 2026
Read Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms by Ghaith Abu-Zeinah, Gabriela Hobbs, Brandi N Reeves, Abdulraheem Yacoub, Joseph M Scandura (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13294216.txt.
Description
Ghaith Abu-Zeinah and colleagues write a 2026 letter on switching interferon types for myeloproliferative neoplasms. Supply trouble with peginterferon alfa-2a, confirmed by regulators in January 2025, pushed many long-term patients toward ropeginterferon alfa-2b, yet no trial defines the right switch dose. The authors share center experience, where interferon use reaches 42% of polycythemia vera patients.
Their default switch starts ropeginterferon at 100 mcg every two weeks, rising by 50 mcg steps every 2 to 4 weeks to hold response. A faster high-dose route may suit patients in partial response on high old doses, but risks side effects and lab problems. No single conversion ratio fits all patients.
Catalog record
| CREATOR | Ghaith Abu-Zeinah, Gabriela Hobbs, Brandi N Reeves, Abdulraheem Yacoub, Joseph M Scandura |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 9249 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |